The team said that the cell death caused by a brain injury such as a stroke or head injury enhances formation of brain-clogging amyloid plaques by means of a molecular chain reaction
In a series of experiments, they showed that "executioner" enzymes that kill brain cells during stroke or head trauma also interfere with the normal disposal of an enzyme that helps generate the plaques that are a hallmark of the illness.
This interference increases the level of the enzyme BACE in brain cells, they found.
BACE snips apart a brain protein called amyloid precursor protein to form a shorter protein called A beta peptide. It is this A beta peptide that is the building block for the amyloid plaques that clog up the brains of Alzheimer's patients.
Essentially, you've got an inhibitor of an inhibitor system going on, which forunately is easy to detect empirically, but more challenging to address therapeutically.
And it's important to get on this trail now, as the future looks to balloon Alzheimer's diagnoses. It appears, however, that the industry is going to capitalize on this to everyone's benefit. Pure science only goes so far, right?